Evidence map›Paper›PMID 31861795›Full record

ArticleMolecules (Basel, Switzerland)2019

Antitumor Effect of a Novel Spiro-Acridine Compound is Associated with Up-Regulation of Th1-Type Responses and Antiangiogenic Action.

Daiana K Frade Silva, Sâmia S Duarte, Thaís M H Lisboa, Rafael C Ferreira, Ana Luíza de O Lopes, Deyse C M Carvalho, Sandra Rodrigues-Mascarenhas, Patricia Mirella da Silva, Miguel A S Pinheiro Segundo, Ricardo O de Moura and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Acridine as an Anti-Tumour Agent: A Critical Review.Molecules (Basel, Switzerland) · 2022
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Daiana K Frade SilvaPost Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, PB 58051-970, Brazil.
Sâmia S DuartePost Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, PB 58051-970, Brazil.
Thaís M H LisboaPost Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, PB 58051-970, Brazil.
Rafael C FerreiraPost Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, PB 58051-970, Brazil.
Ana Luíza de O LopesPost Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, PB 58051-970, Brazil.
Deyse C M CarvalhoMulticenter Postgraduate Program in Physiological Sciences, Federal University of Paraíba, João Pessoa, PB 58051-970, Brazil.ORCID 0000-0002-6987-262X
Sandra Rodrigues-MascarenhasPost Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, PB 58051-970, Brazil.
Patricia Mirella da SilvaDepartment of Molecular Biology, Federal University of Paraíba, João Pessoa, PB 58051-970, Brazil.ORCID 0000-0001-9687-0235
Miguel A S Pinheiro SegundoPost Graduation Program in Pharmaceutical Sciences, Federal University of Pernambuco, Recife, PE 50670-901, Brazil.
Ricardo O de MouraDrug Development and Synthesis Laboratory, Department of Pharmacy, State University of Paraíba, João Pessoa, PB 58070-450, Brazil.
Karina C P MedeirosDepartment of Morphology, Federal University of Rio Grande do Norte, Natal, RN 59078-970, Brazil.
Marianna V SobralPost Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, PB 58051-970, Brazil.ORCID 0000-0002-7740-034X
Universidade Federal da Paraíba · BRUniversidade Estadual da Paraíba · BRUniversidade Federal de Pernambuco · BRUniversidade Federal do Rio Grande do Norte · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor cells have specific features, including angiogenesis induction, cell cycle dysregulation, and immune destruction evasion. By inducing a T helper type 2 (Th2) immune response, tumor cells may favor immune tolerance within the tumor, which allows progression of cancer growth. Drugs with potential antitumor activity are the spiro-acridines, which is a promising new class of acridine compounds. Herein, the novel spiro-acridine (

Indexed as

AcridinesAngiogenesis InhibitorsAntineoplastic AgentsCarcinoma, Ehrlich TumorAnimalsGene Expression Regulation, NeoplasticMiceTh1 CellsUp-RegulationAcridinesAngiogenesis InhibitorsAntineoplastic Agentsangiogenesisantitumor activityimmune responsespiro-acridine compound

Identifiers

PMID31861795
PMCPMC6982894
OpenAlexW2996092211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.